Pharmaceuticals US

US Chronic Kidney Disease Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Chronic Kidney Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.57 Bn Placeholder estimate
Estimate 2025 $5.84 Bn 36.5% of the global market
Projected 2034 $8.99 Bn 53.8% Adds $3.14 Bn over 9 forecast years
CAGR 2025–2034 4.9% Faster than 36% of 180 Pharmaceuticals markets here
Key players 5
  • US is 36.46% of the global market.
  • In North America, the largest is US (this report) at $5.84 Bn.
  • Fastest growing: Canada at 6.8% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.14 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Chronic Kidney Disease Drugs Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.57 Bn — —
2025 (base) $5.84 Bn +$272.9 Mn —
2026 (forecast) $6.13 Bn +$286.3 Mn +4.9%
2027 (forecast) $6.43 Bn +$300.4 Mn +10%
2028 (forecast) $6.75 Bn +$315.1 Mn +15.4%
2029 (forecast) $7.08 Bn +$330.5 Mn +21.1%
2030 (forecast) $7.42 Bn +$346.7 Mn +27%
2031 (forecast) $7.79 Bn +$363.7 Mn +33.2%
2032 (forecast) $8.17 Bn +$381.5 Mn +39.8%
2033 (forecast) $8.57 Bn +$400.2 Mn +46.6%
2034 (forecast) $8.99 Bn +$419.8 Mn +53.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Chronic Kidney Disease Drugs Market Analysis at a glance
Market size, 2025$5.84 Bn placeholder estimate
Forecast, 2034$8.99 Bn placeholder estimate
Growth (CAGR), 2025–20344.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, stage and end user (see all)
Key playersAstraZeneca, Boehringer Ingelheim GmbH, Bayer AG, Novo Nordisk A/S, Amgen Inc. (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials284 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Chronic Kidney Disease Drugs Market Analysis Executive Summary

Chronic kidney disease drugs slow kidney damage and its complications, including SGLT2 inhibitors and newer agents.

Key segments of the chronic Kidney Disease Drugs market include drug class (SGLT2 Inhibitors, ACE Inhibitors and ARBs and Non-Steroidal MRAs) and stage (Stage 1-3 and Stage 4-5).

Bar chart: US Chronic Kidney Disease Drugs market size, 2024–2034, placeholder estimates. $5.57 Bn in 2024, $5.84 Bn in 2025 and $8.99 Bn in 2034, 4.9% CAGR.
US Chronic Kidney Disease Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Chronic Kidney Disease Drugs Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the chronic Kidney Disease Drugs market.

Opportunity

Earlier screening, new drug classes and home-based care give the chronic Kidney Disease Drugs market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the chronic Kidney Disease Drugs market.

Competitive Landscape for Chronic Kidney Disease Drugs Market in the US

The chronic Kidney Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Chronic Kidney Disease Drugs Market in the US

Chronic Kidney Disease Drugs in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 284 studies on Chronic Kidney Disease Drugs that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for chronic Kidney Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in the US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Chronic Kidney Disease Drugs right now, from free public sources.

Clinical trials

284 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 15 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Bayer AG 8 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novartis AG 6 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Novo Nordisk A/S 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Eli Lilly and Company 5 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Chronic Kidney Disease Drugs in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Chronic Kidney Disease Drugs market in the US?
Placeholder estimate: about $5.84 Bn in 2025, rising to about $8.99 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Chronic Kidney Disease Drugs market in the US growing?
Placeholder estimate: about 4.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Chronic Kidney Disease Drugs market report cover?
The report splits the market by drug class (SGLT2 Inhibitors, ACE Inhibitors and ARBs, Non-Steroidal MRAs, Anemia Drugs), stage (Stage 1-3, Stage 4-5) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Chronic Kidney Disease Drugs market?
Key players include AstraZeneca, Boehringer Ingelheim GmbH, Bayer AG, Novo Nordisk A/S and Amgen Inc..
What is driving the Chronic Kidney Disease Drugs market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the chronic Kidney Disease Drugs market.
Who regulates Chronic Kidney Disease Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Chronic Kidney Disease Drugs are running in the US?
284 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Chronic Kidney Disease Drugs?
PubMed lists 25,129 papers on Chronic Kidney Disease Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on kidney health and diabetes

See the topic